

# Synthesis and antimicrobial activity of new 1,2,4-triazole and 1,3,4-thiadiazole derivatives

TIJEN ÖNKOL¹, DENIZ S. DOĞRUER¹, LEYLA UZUN¹, SELCEN ADAK¹, SEMIHA ÖZKAN², & M. FETHI SAHIN¹

<sup>1</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey, and <sup>2</sup>Department of Microbiology, Faculty of Pharmacy, Gazi University, Ankara, Turkey

(Received 5 January 2007; accepted 28 February 2007)

#### **Abstract**

In this study, new 3-[(1(2H)-phthalazinone-2-yl(methyl/ethyl]-4-aryl-1,2,4-triazole-5-thione and 2-[[1(2H)-phthalazinone-2-yl]methyl/ethyl]-5-arylamino-1,3,4-thiadiazole derivatives were synthesized. Antimicrobial properties of the title compounds were investigated against two Gram (+) bacteria (S. aureus, B. subtilis), two Gram (-) bacteria (P. aeruginosa, E. coli) and two yeast-like fungi (C. albicans and C. parapsilosis) using the broth microdilution method. Generally the compounds were found to be active against B. subtilis and the fungi. Derivatives carrying a 1,3,4-thiadiazole ring generally showed higher antimicrobial activity against B. subtilis and the fungi when compared to other synthesized compounds.

**Keywords:** Phthalazinone, 1,2,4-triazole, 1,3,4-thiadiazole, antimicrobial activity

#### Introduction

Since resistance of pathogenic bacteria towards available antibiotics is rapidly becoming a major world-wide problem, the design of new compounds to deal with resistant bacteria has become one of the most important areas of antibacterial research today. In addition, it is known that antifungal drugs do not have selective activity because of the biochemical similarity between human cell and fungi forms. Therefore, there are many studies focused on antibacterial and antifungal compounds [1–3].

Some compounds bearing a 1,2,4-triazole and 1,3,4-thiadiazole structure have been reported to have antimicrobial activity [4–8]. In addition, many compounds carrying a phthalazinone ring have been reported to have diverse biological activities such as antimicrobial [9,10], antihypertensive [11], analgesic and anti-inflammatory activities [12].

In the design of new compounds, development of hybrid molecules through the combination of different pharmacophores in one structure may lead to compounds with increased antimicrobial activity. Therefore, these observations prompted us to synthesize new 1,2,4-triazole and 1,3,4-thiadiazole derivatives which were attached to position-2 of the phthalazinone ring through a methylene or ethylene bridge. Then, the synthesized compounds were tested against two Gram (+) bacteria (Staphylococcus aureus, Bacillus subtilis), two Gram (-) bacteria (Pseudomonas aeruginosa, Escherichia coli) and two yeast-like fungi Candida albicans and Candida parapsilosis using the broth microdilution method.

#### **Experimental**

Chemistry

All the chemicals used for the synthesis of the compounds were purchased from either Aldrich Chemicals or Merck AG. Melting points were determined with an Electrothermal-9300 digital melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin–Elmer 1330 IR

Correspondence: T. Önkol, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330 Etiler-Ankara, Turkey. Tel: 90 312 20232 33. Fax: 90 312 223 50 18. E-mail: tijen@gazi.edu.tr

ISSN 1475-6366 print/ISSN 1475-6374 online © 2008 Informa UK Ltd. DOI: 10.1080/14756360701408697

spectrophotometer and <sup>1</sup>H-NMR spectra on a Mercury 400 FT NMR spectrometer using tetramethylsilane as the internal standard and DMSO-d<sub>6</sub> as solvent. All chemical shifts were recorded as δ (ppm). Elemental analyses were performed with CHNS-932 (Leco) at Ankara University, Faculty of Pharmacy.

General procedure for [1(2H)-phthalazinone-2-yl]acetyl/propanoylthiosemicarbazides (6a-l). To a solution of the [1(2H)-phthalazinone-2-yl]acetyl-hydrazine (0.0025 mol) in 50 mL methanol or the 3-[1(2H)-phthalazinone-2-yl]propanoylhydrazine (0.0025 mol) in 50 mL ethanol were added the appropriate isothiocyanate derivatives (0.0026 mol) and then each reaction mixture was refluxed until the starting material had been consumed. At the end of this period the precipitating product was filtered and crystallized from an appropriate solvent.

- 6a. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1675, 1647; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.41 (1H, s, CON*H*), 9.78 (1H, s, NHN*H*CSNH), 9.51 (1H, s, NHNHCSN*H*), 8.47 (1H, s, H<sup>4</sup>), 8.22 (1H, d, H<sup>8</sup>), 7.97-7.88 (3H, m, H<sup>5</sup>,H<sup>6</sup>,H<sup>7</sup>), 7.50 (2H, d, phenyl-H<sup>2,6</sup>), 7.34 (2H, t, phenyl-H<sup>3,5</sup>), 7.16 (1H, t, phenyl-H<sup>4</sup>), 4.90 (2H, s, CH<sub>2</sub>).
- **6b.** IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1679, 1656; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.23(1H, s, CON*H*), 9.52 (1H, s, NHN*H*CSNH), 8.45 (1H, s, NHNHCSN*H*), 8.42 (1H, s, H<sup>4</sup>), 8.15 (1H,d, H<sup>8</sup>), 7.95-7.84 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.27-7.26 (5H, m, phenyl-H), 4.85 (2H, s, CH<sub>2</sub>), 4.74 (2H, d, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>).
- 6c. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1685, 1650; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.22(1H, s, CON*H*), 9.46 (1H, s, NHN*H*CSNH), 8.48 (1H, s, H<sup>4</sup>), 8.26 (1H,d, H<sup>8</sup>), 8.06 (1H, s, NHNHCSN*H*), 8.00-7.88 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.32-7.18 (5H, m, phenyl-H), 4.87 (2H, s, CH<sub>2</sub>), 3.66-3.64 (2H, m, C*H*<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 2.84 (2H, t, CH<sub>2</sub>C*H*<sub>2</sub>C<sub>6</sub>H<sub>5</sub>).
- **6d.** IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1674, 1645; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 10.47 (1H, s, CON*H*), 9.93 (1H, s, NHN*H*CSNH), 9.59 (1H, s, NHNHCSN*H*), 8.50 (1H, s, H<sup>4</sup>), 8.26 (1H,d, H<sup>8</sup>), 8.00-7.89 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.58 (2H, d, phenyl-H<sup>2,6</sup>), 7.43 (2H, t, phenyl-H<sup>3,5</sup>), 4.93 (2H, s, CH<sub>2</sub>).
- 6e. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1685,1648; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.38 (1H, s, CONH), 9.68 (1H, s, NHNHCSNH), 9.46 (1H, s, NHNHCSNH), 8.48 (1H, s, H<sup>4</sup>), 8.24 (1H,d, H<sup>8</sup>), 7.99-7.88 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.36 (2H, d, phenyl-H<sup>2,6</sup>), 6.93 (2H, t, phenyl-H<sup>3,5</sup>), 4.92 (2H, s, CH<sub>2</sub>), 3.76 (3H, s, OCH<sub>3</sub>).
- **6f.** IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1675,1647; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 10.42 (1H, s,

- CON*H*), 9.75 (1H, s, NHN*H*CSNH), 9.48 (1H, s, NHNHCSN*H*), 8.49 (1H, s, H<sup>4</sup>), 8.24 (1H,d, H<sup>8</sup>), 8.01-7.89 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.38 (2H, d, phenyl-H<sup>2,6</sup>), 7.16 (2H, t, phenyl-H<sup>3,5</sup>), 4.92 (2H, s, CH<sub>2</sub>), 2.30 (3H, s, CH<sub>3</sub>).
- 6g. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1701, 1632; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.03(1H, s, CON*H*), 9.56 (2H, s, NHN*H*CSN*H*), 8.41 (1H, s, H<sup>4</sup>), 8.16 (1H,d, H<sup>8</sup>), 7.93-7.81 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.42 (2H, d, phenyl-H<sup>2,6</sup>), 7.32 (2H, t, phenyl-H<sup>3,5</sup>), 7.16 (1H, t, phenyl-H<sup>4</sup>), 4.39 (2H, t, NC*H*<sub>2</sub>), 2.68 (2H, t, C*H*<sub>2</sub>CO).
- 6h. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1706, 1637; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 9.93 (1H, s, CON*H*), 9.34 (1H, s, NHN*H*CSNH), 8.43 (1H, s, NHNHCSN*H*), 8.41 (1H, s, H<sup>4</sup>), 8.15 (1H,d, H<sup>8</sup>), 7.93-7.81 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.30-7.21 (5H, m, phenyl-H), 4.77 (2H, d, C*H*<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 4.39 (2H, t, NC*H*<sub>2</sub>), 2.65 (2H, t, C*H*<sub>2</sub>CO).
- 6i. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1699, 1641; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 9.83 (1H, s, CONH), 9.21 (1H, s, NHNHCSNH), 8.43 (1H, s, H<sup>4</sup>), 8.24 (1H,d, H<sup>8</sup>), 7.97 (1H, s, NHNHCSNH), 7.94-7.83 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.29-7.15 (5H, m, phenyl-H), 4.37 (2H, t, NCH<sub>2</sub>), 3.64-3.60 (2H, m, CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 2.79 (2H, t, CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 2.63 (2H, t, CH<sub>2</sub>CO).
- *6j.* IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1672, 1649; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.07 (1H, s, CON*H*), 9.69 (1H, s, NHN*H*CSNH), 9.61 (1H, s, NHNHCSN*H*), 8.45 (1H, s, H<sup>4</sup>), 8.20 (1H,d, H<sup>8</sup>),7.97-7.84 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.49 (2H, d, phenyl-H<sup>2,6</sup>), 7.40 (2H, t, phenyl-H<sup>3,5</sup>), 4.42 (2H, t, NC*H*<sub>2</sub>), 2.70 (2H, t, C*H*<sub>2</sub>CO).
- 6k. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1682,1665; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.01 (1H, s, CONH), 9.47 (1H, s, NHNHCSNH), 9.44 (1H, s, NHNHCSNH), 8.43 (1H, s, H<sup>4</sup>), 8.19 (1H,d, H<sup>8</sup>),7.95-7.83 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.27 (2H, d, phenyl-H<sup>2,6</sup>), 6.91 (2H, t, phenyl-H<sup>3,5</sup>), 4.41 (2H, t, NCH<sub>2</sub>), 3.76 (3H, s, OCH<sub>3</sub>), 2.69 (2H, t, CH<sub>2</sub>CO).
- 6l. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1703, 1633; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 9.99 (1H, s, CON*H*), 9.74 (1H, s, NHN*H*CSNH), 9.48 (1H, s, NHNHCSN*H*), 8.41 (1H, s, H<sup>4</sup>), 8.17 (1H,d, H<sup>8</sup>),7.92-7.82 (3H, m, H<sup>5</sup>, H<sup>6</sup>, H<sup>7</sup>), 7.36 (2H, d, phenyl-H<sup>2,6</sup>), 7.10 (2H, t, phenyl-H<sup>3,5</sup>), 4.39 (2H, t, NC*H*<sub>2</sub>), 2.67 (2H, t, C*H*<sub>2</sub>CO), 2.25 (3H, s, CH<sub>3</sub>).

General procedure for 3-[(1(2H)-phthalazinone-2-yl(methyl]-4-aryl-1,2,4-triazole-5-thiones (7a-f). To a solution of the [1(2H)-phthalazinone-2-yl] acetylthiosemicarbazide (0.001 mol) in 50 mL methanol was added an aqueous solution of  $Na_2CO_3$  (10 mL; 10%) and the

reaction mixture was refluxed for 4h, cooled and then neutralized with glacial acetic acid (10%). The precipitate formed was filtered, washed with water and crystallized from an appropriate solvent.

7a. (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1650; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.97 (1H, s, NH), 8.34 (1H, s, H<sup>4</sup>), 8.06 (1H, d, H<sup>8</sup>), 7.91-7.80 (3H, m, H<sup>5,6,7</sup>), 7.32-7.29 (5H, m, phenyl-H), 5.26 (2H, s, CH<sub>2</sub>). Analysis for C<sub>17</sub>H<sub>13</sub>N<sub>5</sub>OS (335.38); Calcd: C; 60.88, H; 3.91, N; 20.88. Found: C; 60.89, H; 3.99, N; 20.71%.

7b. IR (KBr)  $\nu_{\rm max}$  (cm $^{-1}$ ) 1630;  $^{1}$ H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.97 (1H, s, NH), 8.24 (1H, s, H<sup>4</sup>), 8.08 (1H, d, H<sup>8</sup>), 7.86-7.76 (3H, m, H<sup>5,6,7</sup>), 6.99-6.85 (5H, m, phenyl-H), 5.36 (2H, s, CH<sub>2</sub>), 5.24 (2H, s, CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>OS (349.41); Calcd: C; 61.87, H; 4.33, N; 20.04. Found: C; 61.92, H; 4.33, N; 19.72%.

7c. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1652; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.97 (1H, s, NH), 8.49 (1H, s, H<sup>4</sup>), 8.28 (1H, d, H<sup>8</sup>), 7.98-7.89 (3H, m, H<sup>5,6,7</sup>), 7.31-7.23 (3H, m, phenyl-H<sup>3,4,5</sup>), 7.13 (2H, d, phenyl-H<sup>2,6</sup>), 5.19 (2H, s, CH<sub>2</sub>), 4.18 (2H, t, N-CH<sub>2</sub>-CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>), 2.85 (2H, t, N-CH<sub>2</sub>-CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>). Analysis for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>OS (363.43); Calcd: C; 62.79, H; 4.71, N; 19.27. Found: C; 62.36, H; 4.64, N; 18.97%.

7*d.* IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1634; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.97 (1H, s, NH), 8.34 (1H, s, H<sup>4</sup>), 8.05 (1H, d, H<sup>8</sup>), 7.92-7.82 (3H, m, H<sup>5,6,7</sup>), 7.33 (4H, s, phenyl-H), 5.30 (2H, s, CH<sub>2</sub>). Analysis for C<sub>17</sub>H<sub>12</sub>ClN<sub>5</sub>OS (369.83); Calcd: C; 55.21, H; 3.27, N; 18.94. Found: C; 55.28, H; 3.37, N; 18.87%.

7e. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1647; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.86 (1H, s, NH), 8.35 (1H, s, H<sup>4</sup>), 8.06 (1H, d, H<sup>8</sup>), 7.92-7.81 (3H, m, H<sup>5,6,7</sup>), 7.18 (2H, d, phenyl-H<sup>3,5</sup>), 6.80 (2H, d, phenyl-H<sup>2,6</sup>), 5.25 (2H, s, CH<sub>2</sub>), 3.64 (3H, s, OCH<sub>3</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub>S (365.41); Calcd: C; 59.16, H; 4.14, N; 19.17. Found: C; 58.85, H; 4.05, N; 18.80%.

7f. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1665; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.87 (1H, s, NH), 8.34 (1H, s, H<sup>4</sup>), 8.05 (1H, d, H<sup>8</sup>), 7.93-7.80 (3H, m, H<sup>5,6,7</sup>), 7.14 (2H, d, phenyl-H<sup>3,5</sup>), 7.07 (2H, d, phenyl-H<sup>2,6</sup>), 5.25 (2H, s, CH<sub>2</sub>), 2.16 (3H, s, CH<sub>3</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>OS (349.41); Calcd: C; 61.87, H; 4.33, N; 20.04. Found: C; 62.00, H; 4.32, N; 19.95%.

General procedure for 3-[(1(2H)-phthalazinone-2-yl(ethyl]-4-aryl-1,2,4-triazole-5-thiones (7<math>g-l). A NaOH pellet (0.01 mol) was added a solution of the [1(2H)-phthalazinone-2-yl] propanoylthiosemicarbazide (0.001 mol) in 50 mL ethanol and the mixture

was refluxed until the starting material had been consumed. At the end of this period, the resulting solution was poured into ice water and neutralized with glacial acetic acid (10%). The precipitate formed was filtered, washed with water and crystallized from an appropriate solvent.

7g. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1635; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 13.65 (1H, s, NH), 8.39 (1H, s, H<sup>4</sup>), 8.19 (1H, d, H<sup>8</sup>), 7.94-7.85 (3H, m, H<sup>5,6,7</sup>), 7.52-7.41 (5H, m, phenyl-H), 4.26 (2H, t, phthalazinone-C $H_2$ CH<sub>2</sub>), 2.29 (2H, t, phthalazinone-C $H_2$ CH<sub>2</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>OS (349.41); Calcd: C; 61.87, H; 4.33, N; 20.04. Found: C; 61.83, H; 4.13, N; 20.22%.

7*h*. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1626; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.68 (1H, s, NH), 8.39 (1H, s, H<sup>4</sup>), 8.22 (1H, d, H<sup>8</sup>), 7.94-7.85 (3H, m, H<sup>5,6,7</sup>), 7.34-7.26 (5H, m, phenyl-H), 5.30 (2H, s, C $H_2$ -C<sub>6</sub>H<sub>5</sub>), 4.36 (2H, t, phthalazinone-C $H_2$ CH<sub>2</sub>), 3.04 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>OS (363.43); Calcd: C; 62.79, H; 4.41, N; 19.27. Found: C; 62.52, H; 4.71, N; 19.23%.

7*i*. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1653; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.53 (1H, s, NH), 8.44 (1H, s, H<sup>4</sup>), 8.25 (1H, d, H<sup>8</sup>), 7.95-7.85 (3H, m, H<sup>5,6,7</sup>), 7.31-7.20 (5H, m, phenyl-H), 4.36 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 4.14 (2H, t, N-CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 3.02 (2H, t, N-CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 2.87 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>OS (377.46); Calcd: C; 63.64, H; 5.07, N; 18.55. Found: C; 63.28, H; 5.07, N; 18.48%.

*7j.* IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1634; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 13.70 (1H, s, NH), 8.39 (1H, s, H<sup>4</sup>), 8.19 (1H, d, H<sup>8</sup>), 7.94-7.84 (3H, m, H<sup>5,6,7</sup>), 7.57 (2H, d, phenyl-H<sup>3,5</sup>), 7.50 (2H, d, phenyl-H<sup>2,6</sup>), 4.26 (2H, t, phthalazinone-C $H_2$ CH<sub>2</sub>), 2.98 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>18</sub>H<sub>14</sub>ClN<sub>5</sub>OS (383.85); Calcd: C; 56.32, H; 3.68, N; 18.24. Found: C; 56.24, H; 3.69, N; 18.12%.

7**k**. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1633; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 13.60 (1H, s, NH), 8.40 (1H, s, H<sup>4</sup>), 8.19 (1H, d, H<sup>8</sup>), 7.94-7.86 (3H, m, H<sup>5,6,7</sup>), 7.33 (2H, d, phenyl-H<sup>3,5</sup>), 7.01 (2H, d, phenyl-H<sup>2,6</sup>), 4.26 (2H, t, phthalazinone-C $H_2$ CH<sub>2</sub>), 3.35 (3H, s, OCH<sub>3</sub>), 2.94 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>OS (363.43); Calcd: C; 62.79, H; 4.71, N; 19.27. Found: C; 62.37, H; 4.79, N; 19.18%.

7*l*. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1634; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 13.62 (1H, s, NH), 8.39 (1H, s, H<sup>4</sup>), 8.19 (1H, d, H<sup>8</sup>), 7.94-7.84 (3H, m, H<sup>5,6,7</sup>), 7.27 (4H, s, phenyl-H), 4.26 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 2.95 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 2.34 (3H, s, CH<sub>3</sub>). Analysis for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>S (379.73); Calcd: C; 60.14, H; 4.52, N; 18.46. Found: C; 60.01, H; 4.55, N; 18.46%.

General procedure for 2-[(phthalazinone-2-yl(methyl]-5-arylamino-1,3,4-thiadiazoles (8a-f). The appropriate [1(2H)-phthalazinone-2-yl]acetylthiosemicarbazide derivative (0.001 mol) was added portion-wise to H<sub>2</sub>SO<sub>4</sub> (5 mL) cooled in an ice bath with constant stirring. After dissolution, the reaction mixture was further stirred for 30 min, poured over crushed ice and neutralized by saturated Na<sub>2</sub>CO<sub>3</sub> solution at room temperature. Then the solid material was filtered, washed with water and crystallized from an appropriate solvent.

8a. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1645; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 10.32 (1H, s, NH), 8.51 (1H, s, H<sup>4</sup>), 8.30 (1H, d, H<sup>8</sup>), 7.98-7.88 (3H, m, H<sup>5,6,7</sup>), 7.55 (2H, d, phenyl-H<sup>2,6</sup>), 7.31 (2H, t, phenyl-H<sup>3,5</sup>), 6.97 (1H, t, phenyl-H<sup>4</sup>), 5.55 (2H, s, CH<sub>2</sub>). Analysis for C<sub>17</sub>H<sub>13</sub>N<sub>5</sub>OS (335.38); Calcd: C; 60.88, H; 3.91, N; 20.88. Found: C; 60.85, H; 3.64, N; 21.00%.

8b. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1648; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 8.46 (1H, s, H<sup>4</sup>), 8.25 (1H, d, H<sup>8</sup>), 8.21 (1H, t, NH),7.94-7.85 (3H, m, H<sup>5,6,7</sup>), 7.30-7.21 (5H, m, phenyl-H), 5.43 (2H, s, CH<sub>2</sub>), 4.41 (2H, d, NH-CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>OS (349.41); Calcd: C; 61.87, H; 4.33, N; 20.04. Found: C; 62.08, H; 4.36, N; 20.10%.

8c. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1668; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 8.51 (1H, s, H<sup>4</sup>), 8.29 (1H, d, H<sup>8</sup>), 7.98-7.90 (3H, m, H<sup>5,6,7</sup>), 7.82 (1H, t, NH), 7.29-7.17 (5H, m, phenyl-H), 5.46 (2H, s, CH<sub>2</sub>), 3.46 (2H, q, NH-CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 2.84 (2H, t, NH-CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>). Analysis for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>OS (363.43); Calcd: C; 62.79, H; 4.71, N; 19.27. Found: C; 62.20, H; 4.68, N; 19.05%.

8d. IR (KBr)  $\nu_{\rm max}$  (cm $^{-1}$ ) 1643;  $^{1}$ H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 10.46 (1H, s, NH), 8.51 (1H, s, H<sup>4</sup>), 8.29 (1H, d, H<sup>8</sup>), 7.98-7.88 (3H, m, H<sup>5,6,7</sup>), 7.60 (2H, d, phenyl-H<sup>2,6</sup>), 7.36 (2H, t, phenyl-H<sup>3,5</sup>), 5.56 (2H, s, CH<sub>2</sub>). Analysis for C<sub>17</sub>H<sub>12</sub>ClN<sub>5</sub>OS (369.82); Calcd: C; 55.21, H; 3.27, N; 18.94. Found: C; 54.82, H; 3.20, N; 18.69%.

8e. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1645; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 10.10 (1H, s, NH), 8.51 (1H, s, H<sup>4</sup>), 8.28 (1H, d, H<sup>8</sup>), 7.97-7.88 (3H, m, H<sup>5,6,7</sup>), 7.45 (2H, d, phenyl-H<sup>2,6</sup>), 6.89 (2H, d, phenyl-H<sup>3,5</sup>), 5.52 (2H, s, CH<sub>2</sub>), 3.70 (3H, s, OCH<sub>3</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>OS (349.41); Calcd: C; 61.87, H; 4.33, N; 20.04. Found: C; 61.39, H; 4.32, N; 19.75%.

8f. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1636; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 10.20 (1H, s, NH), 8.51 (1H, s, H<sup>4</sup>), 8.28 (1H, d, H<sup>8</sup>), 7.98-7.89 (3H, m, H<sup>5,6,7</sup>), 7.42 (2H, d, phenyl-H<sup>2,6</sup>), 7.11 (2H, d, phenyl-H<sup>3,5</sup>), 5.54 (2H, s, CH<sub>2</sub>), 2.22 (3H, s, CH<sub>3</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub>S (365.41); Calcd: C; 59.16, H; 4.14, N; 19.17. Found: C; 59.12, H; 4.10, N; 18.99%.

General procedure for 2-[(phthalazinone-2-yl(ethyl]-5-arylamino-1,3,4-thiadiazoles (8g-l). [1(2H)-phthalazinone-2-yl]propanoylthiosemicarbazides (0.001 mol) (6) were dissolved in 10 mL toluene and p-toluenesulfonic acid (0.0015 mol) was added and refluxed until the starting material had been consumed. At the end of this period, the reaction mixture was neutralized with 10% ammonium hydroxide. Then the solid material was filtered, washed with water and crystallized from an appropriate solvent.

8g. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1651; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.22 (1H, s, NH), 8.46 (1H, s, H<sup>4</sup>), 8.26 (1H, d, H<sup>8</sup>), 7.96-7.87 (3H, m, H<sup>5,6,7</sup>), 7.54 (2H, d, phenyl-H<sup>2,6</sup>), 7.30 (2H, t, phenyl-H<sup>3,5</sup>), 6.96 (1H, t, phenyl-H<sup>4</sup>), 4.49 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 3.44 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>OS (349.41); Calcd: C; 61.87, H; 4.33, N; 20.04. Found: C; 62.09, H; 4.24, N; 19.99%.

8h. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1645; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 8.44 (1H, s, H<sup>4</sup>), 8.25 (1H, d, H<sup>8</sup>), 8.07 (1H, t, NH), 7.96-7.86 (3H, m, H<sup>5,6,7</sup>), 7.34-7.25 (5H, m, phenyl-H), 4.43-4.40 (4H, m, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>, NH-CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 3.32 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>OS (363.43); Calcd: C; 62.79, H; 4.71, N; 19.27. Found: C; 63.12, H; 4.75, N; 19.23%.

8i. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1647, <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 8.46 (1H, s, H<sup>4</sup>), 8.26 (1H, d, H<sup>8</sup>), 7.96-7.86 (3H, m, H<sup>5,6,7</sup>), 7.67 (1H, t, NH), 7.30-7.18 (5H, m, phenyl-H), 4.43 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 3.42 (2H, q, NH-CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 3.33 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 2.83 (2H, t, NH-CH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>). Analysis for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>OS (377.46); Calcd: C; 63.64, H; 5.07, N; 18.55. Found: C; 63.59, H; 5.18, N; 18.51%.

8j. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1662; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 10.37 (1H, s, NH), 8.46 (1H, s, H<sup>4</sup>), 8.22 (1H, d, H<sup>8</sup>), 7.96-7.88 (3H, m, H<sup>5,6,7</sup>), 7.59 (2H, d, phenyl-H<sup>2,6</sup>), 7.35 (2H, d, phenyl-H<sup>3,5</sup>), 4.49 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 3.44 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>18</sub>H<sub>14</sub>ClN<sub>5</sub>OS (383.85); Calcd: C; 56.32, H; 3.68, N; 18.24. Found: C; 55.45, H; 3.53, N; 17.92%.

8k. IR (KBr)  $\nu_{\rm max}$  (cm<sup>-1</sup>) 1652; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>) δ (ppm) 9.99 (1H, s, NH), 8.44 (1H, s, H<sup>4</sup>), 8.24 (1H, d, H<sup>8</sup>), 7.94-7.86 (3H, m, H<sup>5,6,7</sup>), 7.44 (2H, d, phenyl-H<sup>2,6</sup>), 6.87 (2H, d, phenyl-H<sup>3,5</sup>), 4.46 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>), 3.70 (3H, s, OCH<sub>3</sub>), 3.39 (2H, t, phthalazinone-CH<sub>2</sub>CH<sub>2</sub>). Analysis for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>OS (363.43); Calcd: C; 62.79, H; 4.71, N; 19.27. Found: C; 61.91, H; 4.65, N; 18.86%.

8*l*. IR (KBr)  $\nu_{\text{max}}$  (cm<sup>-1</sup>) 1646; <sup>1</sup>H-NMR (400 MHz) (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 10.10 (1H, s, NH), 8.46 (1H, s,

Comp.	n	R	(Cryst. Sol)	mp	Yield (%)
6a	1	Phenyl	Ethanol	207-209	75
6b	1	Benzyl	Methanol	208	55
6c	1	Phenethyl	Methanol	225	50
6d	1	4-Chlorophenyl	Methanol	237	65
6e	1	4-Methoxyphenyl	Methanol	223-224	60
6f	1	4-Methylphenyl	Methanol	210	65
6g	2	Phenyl	Methanol	205	60
6h	2	Benzyl	Methanol	209,5	45
6 <b>i</b>	2	Phenethyl	Ethanol	196-197	40
6 <b>j</b>	2	4-Chlorophenyl	Ethanol	186	55
6k	2	4-Methoxyphenyl	Ethanol	201	50
61	2	4-Methylphenyl	Ethanol	208	55

Table I. Physicochemical data of [1(2H)-Phthalazinone-2-yl]acetyl/propanoylthiosemicarbazide derivatives (6a-1).

 $\rm H^4$ ), 8.26 (1H, d,  $\rm H^8$ ), 7.96-7.85 (3H, m,  $\rm H^{5,6,7}$ ), 7.42 (2H, d, phenyl- $\rm H^{2,6}$ ), 7.10 (2H, d, phenyl- $\rm H^{3,5}$ ), 4.84 (2H, t, phthalazinone- $\rm CH_2\rm CH_2$ ), 3.44 (2H, t, phthalazinone- $\rm CH_2\rm CH_2$ ), 2.24 (3H, s, CH<sub>3</sub>). Analysis for  $\rm C_{19}\rm H_{17}\rm N_5\rm O_2\rm S$  (379.43); Calcd: C; 60.14, H; 4.52, N; 18.46. Found: C; 60.01, H; 4.55, N; 18.46%.

## Antimicrobial activity

Minimum inhibitory concentration (MIC) values for the synthesized compounds were determined by using the broth microdilution method [13,14]. Two Grampositive (S. aureus ATCC 25923 and B. subtilis ATCC 6633) and two Gram-negative (E. coli ATCC 25922, P. aeruginosa ATCC 27853) bacteria were used as quality control strains. For determining anti-yeast activities of the compounds, the following reference strains were tested: Candida albicans ATCC 10231 and

Candida parapsilosis ATCC 90018. Ampicillin trihydrate and fluconazole were used as standard antibacterial and antifungal agents, respectively. Flucanozole was dissolved in sterile distilled water, ampicillin trihydrate in phosphate buffer (pH 8) and the stock solution of the synthesized compounds was dissolved in dimethyl sulfoxide (DMSO) and distilled water (50%) at a concentration of 2048 μg/mL. Twofold dilutions of the synthesized compounds were dilutions of the reference compounds were prepared at 64-0.125 µg/mL. All bacteria were cultivated in Mueller-Hinton Agar (Merck). The bacteria inoculums was prepared in Mueller-Hinton Broth (Merck) which had been kept at 36°C overnight and was diluted with broth to give a final concentration of  $5 \times 10^5$  cfu/mL. All fungi were cultivated in Sabouraud Dextrose Agar (Merck). The fungi inoculums

Table II.	Physicochemical	data for	the title	compounds (	(7a-1, 8a-1).
Table II.	1 Hysicochichinear	uata 101	the title	compounds (	(/a-1, 0a-1)

Comp.	n	R	Cryst. Sol	Yield (%)	Mp (°C)	
7a	1	Phenyl	Methanol	65	238-240	
7 <b>b</b>	1	Benzyl	Ethanol	45	230-231	
7 <b>c</b>	1	Phenethyl	Methanol	40	231-233	
7 <b>d</b>	1	4-Chlorophenyl	Ethanol	50	239-240	
7e	1	4-Methoxyphenyl	2-Propanol	45	210-211	
$7\mathbf{f}$	1	4-Methylphenyl	Ethanol	55	>300	
7g	2	Phenyl	Ethanol-Water	60	168-170	
7 <b>h</b>	2	Benzyl	Ethanol	40	193-194	
7 <b>i</b>	2	Phenethyl	Methanol	42	216-217	
7 <b>j</b>	2	4-Chlorophenyl	Methanol	50	228-229	
7 <b>k</b>	2	4-Methoxyphenyl	Ethanol	55	225	
71	2	4-Methylphenyl	Methanol	55	239-241	
8a	1	Phenyl	Ethanol	60	228-231	
8b	1	Benzyl	Ethanol	55	170 - 171	
8c	1	Phenethyl	Methanol	50	175-176	
8d	1	4-Chlorophenyl	Ethanol-Water	45	273	
8e	1	4-Methoxyphenyl	Ethanol-Water	50	207	
8 <b>f</b>	1	4-Methylphenyl	Ethanol	55	223	
8g	2	Phenyl	Ethanol	60	202-203	
8h	2	Benzyl	Acetone-P.Ether	55	165-166	
8i	2	Phenethyl	Ethanol	45	161	
8j	2	4-Chlorophenyl	Toluene	50	225-226	
8k	2	4-Methoxyphenyl	Ethanol	55	183-184	
81	2	4-Methylphenyl	Methanol	55	184-185	

were prepared in Sabouraud liquid medium (Oxoid) which had been kept at 36°C overnight and was diluted with RPMI-1640 medium with L-glutamine buffered with 3-[N-morpholino]-propansulfonic acid (MOPS) at pH 7 to give a final concentration of 2.5 × 10<sup>3</sup> cfu/mL. The microplates were incubated at 36°C and read visually after 24 h, except for *Candida* species when it was at 48 h. The incubation chamber was kept humid. At the end of the incubation period, MIC values were recorded as the lowest concentrations of the substances that gave no visible turbidity. The DMSO diluents at a maximum final concentration of 12.5% had no effect on the microorganism's growth.

## Results and discussion

## Chemistry

1(2H)-Phthalazinone was used as the starting material. Synthesis of the compounds 1–3 and [1(2H)-phthalazinone-2-yl]acetylhydrazine were accomplished according to previously reported procedures [12,15]. Methyl [1(2H)-phthalazinone-2-yl]propanoate (SciFinder Scholar 2006, 618441-99-9) and 3-[1(2H)-phthalazinone-2-yl]propanoylhydrazine (618442-00-5) were synthesized according to the available procedures. Synthesis of the novel compounds 6–8 is reported in this study. Structures of the

Scheme 1. Synthetic route for the title compounds.

n=1,2

Compounds	Staphylococcus aureus ATCC 25923	Bacillus subtilis ATCC 6633	Escherichia coli ATCC 25922	Pseudomonas aeruginosa ATCC 27853	Candida albicans ATCC 10231	Candida parapsilosis ATCC 90018
7a	512	512	256	256	512	512
7 <b>b</b>	512	32	256	256	128	64
7 <b>c</b>	256	256	128	256	32	32
7 <b>d</b>	512	64	256	256	512	512
7e	512	32	256	256	512	512
7 <b>f</b>	512	64	256	256	512	512
7g	512	64	256	256	512	256
7 <b>h</b>	512	64	256	256	64	64
7 <b>i</b>	512	32	256	256	256	32
7 <b>j</b>	512	64	256	256	512	512
7 <b>k</b>	512	64	256	256	64	32
71	512	64	256	256	512	512
8a	512	16	128	256	512	64
8b	128	32	128	256	128	64
8c	256	64	128	256	32	32
8d	256	256	128	512	32	32
8e	256	256	128	512	32	32
8 <b>f</b>	512	256	128	512	128	32
8g	128	32	256	256	128	16
8 <b>h</b>	256	128	256	256	512	128
8 <b>i</b>	512	32	256	256	32	64

256

256

256

4

Table III. Minimum inhibitory concentrations (MICs, µg/mL) for the title compounds.

title compounds were confirmed by IR, <sup>1</sup>H-NMR and elemental analyses. [1(2H)-Phthalazinone-2-yl]acetyl/propanoylthiosemicarbazide derivatives (6a-1) were prepared by the reaction of [1(2H)-phthalazinone-2-yl]acetyl/propanoylhydrazine with the appropriate isothiocyanate derivative in methanol or ethanol. [1(2H)-Phthalazinone-2-yl]acetyl/propanoylthiosemicarbazide derivatives (6a-1) were cyclized to the corresponding 3-[(1(2H)-phthalazinone-2-yl(methyl/ethyl]-4-aryl-1,2,4-triazole-5-thione derivatives (7a-1) under alkaline conditions. The other title compounds, 2-[(phthalazinone-2-yl(methyl/ethyl]-5-arylamino-1,3,4-thiadiazole derivatives (8a-1) were obtained by the cyclization of [1(2H)-phthalazinone-2-yl]-acetyl/propanoylthiosemicarbazide derivatives (7a-1) under acidic conditions.

512

512

512

4

128

32

32

8

8j

8k

81

Ampicillin

Fluconazole

In this study, we selected aromatic isothiocyanate derivatives to synthesize the acyl thiosemicarbazide derivatives, since the acyl thiosemicarbazides carrying an aromatic substituents gave good yield when cyclized to 1,2,4-triazole and 1,3,4-thiadiazole derivatives. In addition, we preferred to synthesize 1,2,4-triazole and 1,3,4-thiadiazole derivatives which were attached at position-2 of the phthalazinone ring through methylene or ethylene bridges, since many compounds that carry 1,2,4-triazole and 1,3,4-thiadiazole rings have been reported to be attached to other rings through methylene or ethylene bridges in the literature [5,16].

Physicochemical data for the [1(2H)-Phthalazinone-2-yl]acetyl/propanoylthiosemicarbazide derivatives

(6a-1) is given in Table I whereas that for (7a-1) and (8a-1) is given in Table II. The synthetic route for the title compounds is shown in Scheme 1.

128

128

128

8

64

64

16

0.25

#### Antimicrobial activity

512

256

256

The synthesized compounds were tested against two Gram (+) bacteria (S. aureus, B. subtilis), two Gram (-) bacteria (P. aeruginosa, E.coli) and two yeast-like fungi C. albicans and C. parapsilosis using the broth microdilution method. Ampicillin and fluconazole were used as standard antibacterial and standard antifungal agents, respectively.

As shown in Table III, none of the title compounds had activity against S. aureus, P. aeruginosa and E.coli but, generally, the title compounds were found to be active against B. subtilis and the fungi. Derivatives carrying 1,3,4-thiadiazole ring, generally, showed higher antimicrobial activity against B. subtilis and the fungi compared to the other compounds. The antibacterial activity of 8a was 50% of that of ampicillin against B. subtilis. This derivative was found to be more active against B. subtilis when compared to the other synthesized compounds. The antibacterial activity of compounds 7b, 7e, 7i, 8b, 8g, 8i, 8k and 8l was 25% of that of ampicillin against B. subtilis. Therefore it can be suggested that these compounds show promise as antibacterials and worth further work on their derivatives. The antifungal activity

of compounds 7c, 8c–8e and 8i was 25% of that of fluconazole against *C. albicans*. The MIC values of 7k against *C. albicans* and *C. parapsilosis* were determined as 64 μg/mL and 32 μg/mL, respectively. Compound 7i was active against *C. parapsilosis* and its MIC value was 32 μg/mL. Compounds 8g and 8l exhibited antifungal activity with a MIC value of 16 μg/mL against *C. parapsilosis* and these values for 8c–8f against *C. parapsilosis* were 32 μg/mL. Therefore, compounds 7c, 7i, 7k, 8c–8e, 8g, 8i and 8l could be good starting points for developing better antifungal agents against yeast-like fungi. Chain elongation between the two heterocyclic rings may be a good choice for further studies. Additionally, further substitution on the phthalazinone moiety should be studied.

## Acknowledgements

This study was supported by a grant from the Research Foundation of Gazi University (EF 02/2006-01).

#### References

- [1] Gold HS, Moellering RC, Engl N. J Med Chem 1996;335: 1445-1453.
- [2] Bossche VH, Marichal P, Odds FC. Trends Microbiol 1994; 10:393-400.
- [3] Cohen ML. Science 1992;257:1050-1055.

- [4] Terzioğlu N, Karalı N, Gürsoy A, Kiraz M, Erturan Z. Acta Pharmaceutica Turcica XXXX 1998;2:77–82.
- [5] Varvaresou A, Kakolidou AT, Papastaikoudi TS, Tiligada E. Arzneim-Forsch/Drug Res 2000;50(I):48-54.
- [6] Gülerman NN, Doğan HN, Rollas S, Johansson C, Çelik C. Farmaco 2001;56:953–958.
- [7] Servi S, Genç M, Gür S, Koca M. Eur J Med Chem 2005;40: 687–693.
- [8] Dogan HN, Duran A, Rollas S, Sener G, Uysal MK, Gulen D. Bioorg Med Chem 2002;10:2893–2898.
- [9] Kassim EM, Abd-El-Nour KN, El-Diwany AI, Abou-Aiad TH. Ind J Chem 1996;35B:692–696.
- [10] Kassem EM, Kamel MM, El-Zahar M. Pharmazie 1990;45: 215-216.
- [11] Demirayak S, Karaburun AC, Beis R. Eur J Med Chem 2004; 39:1089–1095.
- [12] Doğruer DS, Küpeli E, Yeşilada E, Şahin MF. Arch Pharm Pharm Med Chem 2004;337:303-310.
- [13] National Committee for Clinical Laboratory Standards. Method for broth dilution antifungal susceptibility testing yeast; approved standard, M27-A, 15, 10, NCCLS, VA Medical Center, Tuscon, 1996.
- [14] National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, third ed. Approved standard. NCCLS document M100-S12, NCCLS, Wayne, PA, USA, 2002.
- [15] Hassanien AZ Abd El-Baset. Phosphorus, Sulfur and Silicon and the Related Elements 2003;178:1987–1997.
- [16] El-Masry AH, Fahmy HH, Abdelwahed SHA. Molecules 2000;5:1429–1438.

Copyright of Journal of Enzyme Inhibition & Medicinal Chemistry is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.